Anna Maria Di Giacomo

Author

Also Known As

A GIACOMO, A M Di Giacomo, A. Giacomo, A. M. Di Giacomo, A.M. Di Giacomo, Anna M. Di Giacomo, Anna Maria Di Giacomo, Anna Maria di Giacomo, Di Giacomo, Anna Maria, Giacomo, Anna Maria Di

281

Publications

14.5K

Citations

H-Index

Concepts

All Affiliations

University of Siena Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere Scientifico European Institute of Oncology Melanoma Institute Australia

About

Anna Maria Di Giacomo is an author at University of Siena specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	31	5K
2	Health Sciences	6	6	418
3	Cell Biology	3	3	197
4	Biostatistics	1	1	19
5	Diagnostic Sciences	1	1	27

Anna Maria Di Giacomo

Publications

13.3K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Journal of Clinical Oncology	2019	2.8K
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, The Lancet Oncology MedicineAdvanced Brafv600-mutant MelanomaMelanomaImmune Checkpoint InhibitorDermatology	2016	986
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Benjamin Weide, Alexander Martens, Jessica C. Hassel, Clinical Cancer Research	2016	569
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab Alexander Martens, Kilian Wistuba‐Hamprecht, Marnix Geukes Foppen, Clinical Cancer Research	2016	534
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, The Lancet Oncology OncologyBinimetinib Versus DacarbazineMedicineMelanomaPharmacotherapy	2017	482
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial Antonio Omuro, Alba A. Brandes, Ahmed Idbaïh, Neuro-Oncology	2022	435
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, JAMA Oncology	2020	421
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial Luana Calabrò, Aldo Morra, Ester Fonsatti, The Lancet Oncology Surgical OncologyMalignant DiseaseMedicineCancer ManagementPathology	2013	353
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Paolo A. Ascierto, Georgina V. Long, Caroline Robert, JAMA Oncology	2018	330

Page 1